chidamide
Showing 26 - 50 of 77
Safety and Efficacy Trial in Suzhou (Chidamide)
Recruiting
- Safety and Efficacy
- Chidamide
-
Suzhou, Jiangsu, ChinaFirst Affiliated Hospital,Soochow University
Nov 30, 2021
Leukemia, Myeloid, Acute Trial in Guanzhou (Azacitidine, Chidamide)
Recruiting
- Leukemia, Myeloid, Acute
- Azacitidine
- Chidamide
-
Guanzhou, Guandong, ChinaNanfang Hospital of Southern Medical University
Mar 6, 2022
Leukemia, Leukemia, Acute, Leukemia, Lymphoblastic Trial in Guangzhou (Chidamide, Dasatinib)
Recruiting
- Leukemia
- +3 more
- Chidamide
- Dasatinib
-
Guangzhou, Guangdong, ChinaDepartment of Hematology, Nanfang Hospital
Jun 28, 2022
Peripheral T-Cell Lymphoma Trial in Zhengzhou (Parsaclisib, Chidamide)
Not yet recruiting
- Peripheral T-Cell Lymphoma
- Parsaclisib
- Chidamide
-
Zhengzhou, Henan, ChinaHenan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Dec 26, 2021
Non Hodgkin's Lymphoma Trial in China (Chidamide, Fludarabine and cyclophosphamide, Anti-CD19 CAR-T cells)
Recruiting
- Non Hodgkin's Lymphoma
- Chidamide
- +2 more
-
Beijing, Beijing, China
- +12 more
Jun 9, 2022
Neuroendocrine Tumors, Neuroendocrine Tumor Grade 3, Neuroendocrine Carcinoma Trial in Xiamen, Harbin (Chidamide, Sintilimab)
Recruiting
- Neuroendocrine Tumors
- +3 more
- Chidamide
- Sintilimab
-
Xiamen, Fujian, China
- +1 more
Nov 22, 2021
Advanced Breast Cancer Trial in Shenyang (Chidamide, Fulvestrant)
Recruiting
- Advanced Breast Cancer
- Chidamide
- Fulvestrant
-
Shenyang, Liaoning, ChinaLiangning Tumor Hospital &Institute
Sep 8, 2021
Non Small Cell Lung Cancer Trial in China (Chidamide, Envafolimab)
Recruiting
- Non Small Cell Lung Cancer
- Chidamide
- Envafolimab
-
Hefei, Anhui, China
- +11 more
Jan 17, 2022
Neuroendocrine Tumors, Neuroendocrine Carcinoma Trial in Beijing, Xiamen, Harbin (Chidamide, Etoposide + Cisplatin/Carboplatin)
Recruiting
- Neuroendocrine Tumors
- Neuroendocrine Carcinoma
- Chidamide
- Etoposide + Cisplatin/Carboplatin
-
Beijing, Beijing, China
- +2 more
Nov 2, 2021
Breast Cancer Trial in China (Chidamide, exemestane, )
Completed
- Breast Cancer
- Chidamide
- +2 more
-
Hefei, Anhui, China
- +21 more
Jan 10, 2022
Angioimmunoblastic T-cell Lymphoma Trial in Guangzhou (Sintilimab, Chidamide)
Not yet recruiting
- Angioimmunoblastic T-cell Lymphoma
- Sintilimab
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Apr 2, 2021
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) Trial in Guangzhou (Chidamide)
Recruiting
- Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
- Chidamide
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology, Sun Yat-sen University Cancer Ce
Mar 12, 2021
Safety and Efficacy Trial in Guangzhou (Sintilimab, Chidamide, Azacitidine)
Not yet recruiting
- Safety and Efficacy
- Sintilimab
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Medical Oncology,Sun Yat-sen University Cancer Cen
Aug 16, 2021
Peripheral T-cell Lymphoma Trial in Beijing (Sintilimab, Chidamide, Azacidine)
Not yet recruiting
- Peripheral T-cell Lymphoma
- Sintilimab
- +2 more
-
Beijing, Beijing, ChinaBeijing
Mar 5, 2021
Advanced Microsatellite Stable Colorectal Cancer, Metastatic Microsatellite-stable Colorectal Cancer Trial (Sintilimab,
Not yet recruiting
- Advanced Microsatellite Stable Colorectal Cancer
- Metastatic Microsatellite-stable Colorectal Cancer
- Sintilimab
- +2 more
- (no location specified)
Feb 3, 2021
NSCLC Trial in Guangzhou (Avitinib Maleate, Afatinib, Crizotinib)
Recruiting
- Carcinoma, Non-Small-Cell Lung
- Avitinib Maleate
- +13 more
-
Guangzhou, Guangdong, ChinaGuangdong Lung Cancer Institute, Guangdong Provincial People's H
Dec 3, 2022
Peripheral T Cell Lymphoma Trial in Guangzhou (Mitoxantrone Hydrochloride Liposome Injection, Chidamide)
Not yet recruiting
- Peripheral T Cell Lymphoma
- Mitoxantrone Hydrochloride Liposome Injection
- Chidamide
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Dec 11, 2020
Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell Trial in China (Chidamide, Cladribine, Gemcitabine)
Recruiting
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell
- Chidamide
- +8 more
-
Deyang, Deyang, China
- +10 more
Jul 21, 2022
Lymphoma, Large B-Cell, Diffuse, Mantle Cell Lymphoma, Peripheral T Cell Lymphoma Trial in Nanjing (Chidamide)
Active, not recruiting
- Lymphoma, Large B-Cell, Diffuse
- +3 more
- Chidamide
-
Nanjing, Jiangsu, ChinaHematological Department, People's Hospital of Jiangsu Province
Dec 30, 2021
Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden Trial in Beijing (Chidamide, Decitabine, Chidamide and
Unknown status
- Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden
- Chidamide
- +3 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Dec 3, 2020
Hodgkin Lymphoma Trial in Beijing (Chidamide, Camrelizumab, Decitabine)
Recruiting
- Hodgkin Lymphoma
- Chidamide
- +2 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Aug 12, 2020
Non Hodgkin Lymphoma Trial in Beijing (Chidamide, Decitabine, Camrelizumab)
Recruiting
- Non Hodgkin Lymphoma
- Chidamide
- +2 more
-
Beijing, Beijing, ChinaBiotherapeutic Department of Chinese PLA General Hospital
Apr 4, 2020
Diffuse Large B Cell Lymphoma Trial in Shanghai (Cyclophosphamide, Rituximab, Doxorubicin)
Recruiting
- Diffuse Large B Cell Lymphoma
- Cyclophosphamide
- +8 more
-
Shanghai, Shanghai, ChinaRuijin hospital
Nov 17, 2020